ABOUT LUMINATE
Making Cancer Care More Human
Y-Combinator Backed
Europe's Fastest Growing MedTech Startup

ABOUT LUMINATE
Making Cancer Care More Human
Y-Combinator Backed
Europe's Fastest Growing MedTech Startup

ABOUT LUMINATE
Making Cancer Care More Human
Y-Combinator Backed
Europe's Fastest Growing MedTech Startup

We’re here to reimagine cancer care, because the system isn’t working for the people in it.
We focus on the parts of cancer care that often go overlooked: the side effects, the burden on clinics, and the emotional toll on patients.
Everything we build is shaped by the people who use it - patients, providers, and partners alike.


Trusted by leading healthcare and tech investors

Trusted by leading healthcare and tech investors

Trusted by leading healthcare and tech investors
Our Journey
So Far
2019

Luminate begins
At the University of Galway, when medical device researchers Aaron Hannon, Dr. Bárbara Oliveira, and Prof. Martin O’Halloran were inspired to tackle chemotherapy-related side effects through technology, starting with hair loss. Enterprise Ireland's Commercialisation Fund grant helped kickstart our journey
2019

Luminate begins
At the University of Galway, Aaron Hannon, Dr. Bárbara Oliveira, and Prof. Martin O’Halloran were inspired to address the side effects of chemotherapy through medical device technolgy, starting with hair loss.
2019

Luminate begins
At the University of Galway, when medical device researchers Aaron Hannon, Dr. Bárbara Oliveira, and Prof. Martin O’Halloran were inspired to tackle chemotherapy-related side effects through technology, starting with hair loss. Enterprise Ireland's Commercialisation Fund grant helped kickstart our journey
2021

Spin-out + accelerate into Y Combinator
Joined Y Combinator’s Summer 2021 batch alongside alumni like Airbnb, Stripe, and Dropbox, and validated our hair-loss prevention technology while completing our first fundraise
2021

Spun out of University of Galway, Acclerated into Y Combinator
Joined Y Combinator’s Summer 2021 batch alongside alumni like Airbnb, Stripe, and Dropbox, and validated our hair-loss prevention technology while completing our first fundraise.
2021

Spin-out + accelerate into Y Combinator
Joined Y Combinator’s Summer 2021 batch alongside alumni like Airbnb, Stripe, and Dropbox, and validated our hair-loss prevention technology while completing our first fundraise
2022

Building momentum: Raise €2.1M in DTIF funding, and €2.5M in Seed Funding from SciFounders, Elkstone, and Faber
Secured €4.7M in funding to advance Lily, and support clinical trials across the U.S. and EU. Momentum starts to build from our Galway HQ to New York, we grow our R&D team, welcoming product designers, clinicians, and engineers
2022

Building momentum: Raise €2.1M in DTIF funding, and €2.5M in Seed Funding from SciFounders, Elkstone, and Faber
Secured €4.7M in funding to advance Lily, and support clinical trials across the US and EU. Momentum starts to build from our Galway HQ to New York, we grow our R&D team, adding product designers, clinicians, and engineers.
2022

Building momentum: Raise €2.1M in DTIF funding, and €2.5M in Seed Funding from SciFounders, Elkstone, and Faber
Secured €4.7M in funding to advance Lily, and support clinical trials across the U.S. and EU. Momentum starts to build from our Galway HQ to New York, we grow our R&D team, welcoming product designers, clinicians, and engineers
2023

Awarded second DTIF for €4.4m, demonstrate first evidence of prevention of hair loss and peripheral neuropathy in human chemotherapy patients
2023

Awarded second DTIF for €4.4m, demonstrate first evidence of prevention of hair loss and peripheral neuropathy in human chemotherapy patients
2023

Awarded second DTIF for €4.4m, demonstrate first evidence of prevention of hair loss and peripheral neuropathy in human chemotherapy patients
2024

Raise €15m in Series A funding led by ARTIS and 8VC, start first US-based multi center clinical trial for Lily
2024

Raise €15m in Series A funding led by ARTIS and 8VC, start first US-based multi center clinical trial for Lily
2024

Raise €15m in Series A funding led by ARTIS and 8VC, start first US-based multi center clinical trial for Lily
2025

Launched clinical trials in the U.S. for Lilac, awarded third DTIF for €6.5m, reached 50 team members in Galway
2025

Launched clinical trials in the U.S. for Lilac, awarded third DTIF for €6.5m, reached 50 team members in Galway
2025

Launched clinical trials in the U.S. for Lilac, awarded third DTIF for €6.5m, reached 50 team members in Galway
Featured in
Featured in
Featured in
Meet the team behind the work
Our team brings together clinical insight, technical depth, and a shared belief that better care is possible. Together, we’re building tools that make a measurable difference.
Leadership
Board
Full Team
Meet the team behind the work
Our team brings together clinical insight, technical depth, and a shared belief that better care is possible. Together, we’re building tools that make a measurable difference.
Leadership
Board
Meet the team behind the work
Our team brings together clinical insight, technical depth, and a shared belief that better care is possible. Together, we’re building tools that make a measurable difference.
Leadership
Board
Full Team


On trial at leading
medical institutions





Trusted by leading healthcare and tech investors





Trusted by leading healthcare and tech investors



Building Europe's fastest growing MedTech startup
We’re a team of engineers, designers, clinicians, and researchers working together to make care more human.
Build the future of cancer care with us and help us to help patients.
Building Europe's fastest growing MedTech startup
We're a team of engineers, designers, clinicians, and researchers working together to make care more human
Build the future of cancer care with us and help us to help patients.
Building Europe's fastest growing MedTech startup
We’re a team of engineers, designers, clinicians, and researchers working together to make care more human.
Build the future of cancer care with us and help us to help patients.
We build technologies that help oncologists make cancer care better for patients.
People want to live, not just survive. We are building technology that aims to enable patients to improve their own experience of healthcare.
Information on this website pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration.
FUNDED BY
On Trial At



Featured In
We build technologies that help oncologists make cancer care better for patients.
People want to live, not just survive. We are building technology that aims to enable patients to improve their own experience of healthcare.
Information on this website pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration.
FUNDED BY
On Trial At



Featured In
We build technologies that help oncologists make cancer care better for patients.
People want to live, not just survive. We are building technology that aims to enable patients to improve their own experience of healthcare.
Information on this website pertains to pre-clinical or clinical-stage medical devices in development that have not been approved by the Food and Drug Administration.
FUNDED BY
On Trial At



Featured In